Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina, Macrogen; Abbott; GE Healthcare; Cambio, BellBrook Labs

NEW YORK (GenomeWeb News) – Illumina this week said that Macrogen, a Korea-based sequencing services firm, has purchased an additional 10 HiSeq 2000 systems and two MiSeq systems, in addition to upgrades for its HiSeq 2500. Macrogen also intends to develop diagnostic tests based on the MiSeq platform.

Abbott this week announced that the name for its pharmaceutical business, which will be spun off later this year, will be AbbVie. The firm will be headed by Richard Gonazalez, the current head of global pharmaceuticals for Abbott, and will have around $18 billion in annual revenue. Abbott announced the planned split last October.

GE Healthcare has opened a new Fast Track Training Center in Shanghai, China, primarily for its bioprocessing products. However, the firm said that the center also will be stocked with its In Cell and DeltaVision products for cellular screening and Biacore and Microcal tools for protein interaction studies, enabling it to provide training with these products.

Cambio has been named UK distributor for BellBrook Labs' Transcreener High Throughput Screening assays and iuvo Microconduit Array Platform.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.